Onena Medicines jobs and careers
Switzerland
About Onena Medicines
Onena Medicines is a biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat recurrent and metastatic cancers and selected rare diseases. Onena’s drugs neutralize a new class of secreted ancient growth factors, conserved across species, called Dual SMAD Inhibiting Proteins (DSIPs), that program cancer cells to grow and resist chemotherapy. Blocking DSIPs, as demonstrated in-vivo by Onena, simultaneously reactivates physiological TGF-β and BMP signaling and elicits cellular reprogramming, resulting in cancer cells accepting environmental cell death signals from BMPs and Activins. Onena has developed a proprietary AI-centric antibody drug discovery platform that rapidly generates anti-DSIP neutralizing antibodies, even when no crystal structure of the antigen is available. OMED-101, Onena’s anti-LEFTY1/2 lead candidate antibody, has demonstrated broad efficacy against breast, colorectal and brain cancers without observable toxicities in preclinical models. Through its unique platform, Onena Medicines has discovered several DSIPs and aims to advance multiple neutralizing DSIP antibody drugs into clinical development in the next three years.
Founded in 2019 by Neethan Lobo.
- Founded
- 2019
- Employees
- 1 to 10
- Total funding
- $6.4M
- Headquarters
- Switzerland
Leadership
The top of Onena Medicines's org chart, with how many people report into each leader.
Neethan Lobo
CEO and Co-founder
Jobs at Onena Medicines
No open positions right now. Explore more companies on TheJobsMap.